Preventive trial for Covid-19
Research type
Research Study
Full title
Safety and efficacy of Autologous Gold-activated Serum for at risk populations against COVID-19 virus infection - a randomized, double-blind, placebo-controlled, multicenter trial-
IRAS ID
291791
Contact name
Ulrich Schneider
Contact email
Sponsor organisation
Patient Choice International
Duration of Study in the UK
0 years, 8 months, 3 days
Research summary
The Coronavirus Disease 2019 (COVID-19) pandemic has placed tremendous stress on the global economy and healthcare systems, it has taken and keeps taking many lives and leaves many with adverse complications since its outbreak in December 2019. Despite numerous scientific activities there is still no effective way to contain the disease. The transmission of COVID-19 occurs via direct (prolonged close interaction, within 2 meters for more than 30 minutes) and indirect (fomites) contacts. Exemplary, the risk of COVID-19 nosocomial infections of hospital workers in intensive care units (ICU) is about 4%. Other exemplary groups are nursing home probands with co-morbidities and their direct relatives, nursing home personell, immunosupressed probands or people with recurrent viral infestations. Especially for those groups, which are at risk but also for general public it would be very advantageous to have a single effective, safe, sustainable and affordable therapeutic agent available that could prevent us from those infections.
REC name
London - City & East Research Ethics Committee
REC reference
20/HRA/5723
Date of REC Opinion
18 Dec 2020
REC opinion
Unfavourable Opinion